Recent studies investigated the effect of novel hERG activators (Bentzen et al, 2011; Zhang et al, 2012; Bebernitz et al, 2015; Giacomini et al, 2015; Mannikko et al, 2015; Bossu et al, 2016; Yu et al, 2016), which indicated that there is significant interest from academia and pharma in developing small molecules to increase the rapid component of the delayed rectifying potassium current (IKr) conducted by hERG channel, since this could counteract both congenital and acquired LQTS. Here, KCNH2 is linked to familial long QT syndrome.